Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.97 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 7/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | TSHR | P16473 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.97 |
| ▸ | MTOR | P42345 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.97 |
| ▸ | DRD2 | P14416 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL4165 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3253794 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29386243 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL250806 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL29620666 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29519146 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4166 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL1333049 | 0.97 | MAPT (0.97) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.97 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0837681-B1 | USE OF 19-NOR-VITAMIN D COMPOUNDS FOR THE PREVENTION OF HYPERPHOSPHATEMIA IN KIDNEY DISORDER PATIENTS | WISCONSIN ALUMNI RES FOUND (US) | 2005-03-16 | — | — | EP | disclosed |
| US-6239144-B1 | ADMINISTERING A TACHYKININ RECEPTOR ANTAGONIST, 2-(N-(2-((4-CYCDOHEXYL)PIPERAZIN-1-YL)ACETYL)AMINO)-3-(1H-INDO L-3-YL)-1-(N-(2-METHOXYBENZYL)ACETYLAMINO)PROPANE, | ELI LILLY AND COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-1998043639-A1 | METHODS OF TREATING BONE LOSS | ELI LILLY AND COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| EP-0837681-A2 | USE OF 19-NOR-VITAMIN D COMPOUNDS FOR THE PREVENTION OF HYPERPHOSPHATEMIA IN KIDNEY DISORDER PATIENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997002826-A2 | USE OF 19-NOR-VITAMIN D COMPOUNDS FOR THE PREVENTION OF HYPERPHOSPHATEMIA IN KIDNEY DISORDER PATIENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-01-30 | — | — | WO | disclosed |
| US-5597815-A | 19-NOR-1A,25-DIHYDROXYVITAMIN D2 FOR ADMNISTERING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-01-28 | — | — | US | disclosed |